Literature DB >> 27867538

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Adrian Rendon1, Simon Tiberi2, Anna Scardigli3, Lia D'Ambrosio4, Rosella Centis5, Jose A Caminero6, Giovanni Battista Migliori5.   

Abstract

Entities:  

Year:  2016        PMID: 27867538      PMCID: PMC5107456          DOI: 10.21037/jtd.2016.10.14

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  36 in total

Review 1.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  José A Caminero; Giovanni Sotgiu; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Lancet Infect Dis       Date:  2010-09       Impact factor: 25.071

2.  Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.

Authors:  Simon Tiberi; Lia D'Ambrosio; Saverio De Lorenzo; Pietro Viggiani; Rosella Centis; Giovanni Sotgiu; Jan Wilem C Alffenaar; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2015-11-19       Impact factor: 16.671

3.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

4.  Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

Authors:  Saverio De Lorenzo; Jan Wilem Alffenaar; Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Simon Tiberi; Mathieu S Bolhuis; Richard van Altena; Piero Viggiani; Andrea Piana; Antonio Spanevello; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-09-20       Impact factor: 16.671

5.  Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.

Authors:  E Cambau; M Viveiros; D Machado; L Raskine; C Ritter; E Tortoli; V Matthys; S Hoffner; E Richter; M L Perez Del Molino; D M Cirillo; D van Soolingen; E C Böttger
Journal:  J Antimicrob Chemother       Date:  2014-11-11       Impact factor: 5.790

6.  Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Authors:  Simon Tiberi; Giovanni Sotgiu; Lia D'Ambrosio; Rosella Centis; Marcos Abdo Arbex; Edith Alarcon Arrascue; Jan Willem Alffenaar; Jose A Caminero; Mina Gaga; Gina Gualano; Alena Skrahina; Ivan Solovic; Giorgia Sulis; Marina Tadolini; Valentina Alarcon Guizado; Saverio De Lorenzo; Aurora Jazmín Roby Arias; Anna Scardigli; Onno W Akkerman; Alena Aleksa; Janina Artsukevich; Vera Auchynka; Eduardo Henrique Bonini; Félix Antonio Chong Marín; Lorena Collahuazo López; Gerard de Vries; Simone Dore; Heinke Kunst; Alberto Matteelli; Charalampos Moschos; Fabrizio Palmieri; Apostolos Papavasileiou; Marie-Christine Payen; Andrea Piana; Antonio Spanevello; Dante Vargas Vasquez; Pietro Viggiani; Veronica White; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2016-04-13       Impact factor: 16.671

7.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Authors:  Vija Skripconoka; Manfred Danilovits; Lea Pehme; Tarmo Tomson; Girts Skenders; Tiina Kummik; Andra Cirule; Vaira Leimane; Anu Kurve; Klavdia Levina; Lawrence J Geiter; Davide Manissero; Charles D Wells
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

8.  Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.

Authors:  Charles D Wells; Rajesh Gupta; Norbert Hittel; Lawrence J Geiter
Journal:  Eur Respir J       Date:  2015-02-19       Impact factor: 16.671

Review 9.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

10.  First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.

Authors:  Marina Tadolini; Rangjung Dolma Lingtsang; Simon Tiberi; Martin Enwerem; Lia D'Ambrosio; Tsetan Dorji Sadutshang; Rosella Centis; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2016-06-10       Impact factor: 16.671

View more
  5 in total

1.  Long-term Follow-up Reveals High Posttreatment Mortality Rate Among Patients With Extensively Drug-Resistant Tuberculosis in the Country of Georgia.

Authors:  Melanie Frank; Natalia Adamashvili; Nino Lomtadze; Eka Kokhreidze; Zaza Avaliani; Russell R Kempker; Henry M Blumberg
Journal:  Open Forum Infect Dis       Date:  2019-03-29       Impact factor: 3.835

2.  International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis.

Authors:  Giovanni Battista Migliori; Rosella Centis; Lia D'Ambrosio; Denise Rossato Silva; Adrian Rendon
Journal:  J Bras Pneumol       Date:  2019-04-25       Impact factor: 2.624

Review 3.  Role of Antimicrobial Peptides in Treatment and Prevention of Mycobacterium Tuberculosis: A Review.

Authors:  Kanchan Mehta; Prince Sharma; Shama Mujawar; Ashish Vyas
Journal:  Int J Pept Res Ther       Date:  2022-07-22       Impact factor: 2.191

Review 4.  Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors:  Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

5.  Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.

Authors:  María Pilar Arenaz-Callao; Rubén González Del Río; Ainhoa Lucía Quintana; Charles J Thompson; Alfonso Mendoza-Losana; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2019-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.